Strong Commercial Growth
Galleri test orders grew significantly with more than 45,000 commercial tests sold in Q2, contributing to over 370,000 tests prescribed since its launch in 2021.
Positive Clinical Trial Results
PATHFINDER 2 study showed substantially greater additional cancer detection and a higher positive predictive value compared to the first PATHFINDER study.
Revenue Growth
GRAIL reported Q2 revenue of $35.5 million, an 11% increase from the same period in 2024, with U.S. Galleri revenue up 21%.
Partnership Expansion
GRAIL established new partnerships, including with Rush University System for Health and Everlywell, to expand the availability of Galleri.
Improved Financials
Net loss improved by 93% compared to Q2 2024, with cash burn guidance updated to no more than $310 million for 2025, down from previously projected numbers.